Status:
RECRUITING
Antihypertensive Mechanisms of Minocycline in Resistant Hypertension
Lead Sponsor:
University of Florida
Collaborating Sponsors:
Emory University
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Hypertension, Resistant to Conventional Therapy
Eligibility:
All Genders
18-100 years
Phase:
PHASE4
Brief Summary
The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer a...
Detailed Description
One hundred twenty patients with treatment-resistant hypertension will be enrolled. A total of 34 patients (17 from each treatment arm), who are participants in the main study, will also be enrolled i...
Eligibility Criteria
Inclusion Criteria:
- Age ≥18 years
- Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥14 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed diuretic or unable to tolerate a diuretic.
- The participant agrees to have all study procedures performed
Exclusion Criteria:
- Known hypersensitivity or contraindication to minocycline or other tetracyclines
- Recent (≤3 months prior), ongoing, or expected use of oral antibiotics
- Estimated glomerular filtration rate (eGFR) of <45mL/min/1.73m2, using the MDRD equation
- Known secondary hypertension
- History of hypertensive crisis, defined as any in-patient hospitalizations for hypertensive crisis/emergency within the past year
- History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of >20 mm Hg or DBP of >10 mm Hg within 3 minutes of standing) in the past year
- History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months
- Evidence of alcoholism or drug abuse
- Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS)
- Current pregnancy or anticipated pregnancy during the study.
Key Trial Info
Start Date :
January 8 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06246396
Start Date
January 8 2025
End Date
July 1 2028
Last Update
March 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UF Clinical Research Center (UF CRC) - CTSI
Gainesville, Florida, United States, 32610